...

首页> 外文期刊>Journal of Clinical Oncology >Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227

【24h】

Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227

机译：甲氨蝶呤，利妥昔单抗和替莫唑胺，全脑放疗和替莫唑胺照射后治疗原发性中枢神经系统淋巴瘤的一期和二期研究：NRG肿瘤学RTOG 0227

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第14期|共8页
作者
Glass Jon; Won Minhee; Schultz Christopher J.; Brat Daniel; Bartlett Nancy L.; Suh John H.; Werner-Wasik Maria; Fisher Barbara Jean; Liepman Marcia K.; Augspurger Mark; Bokstein Felix; Bovi Joseph A.; Solhjem Matthew C.; Mehta Minesh P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献

1. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227 [J] . Glass Jon, Won Minhee, Schultz Christopher J., Journal of Clinical Oncology . 2016,第14期

机译：甲氨蝶呤，利妥昔单抗和替莫唑胺，全脑放疗和替莫唑胺照射后治疗原发性中枢神经系统淋巴瘤的一期和二期研究：NRG肿瘤学RTOG 0227
2. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: Results of the multicenter ostdeutsche studiengruppe H?matologie und onkologie OSHO-53 phase II study [J] . KieferT., HirtC., Sp?thC., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第7期

机译：大剂量化学疗法加自体干细胞移植和适应性全脑放疗对新诊断的原发性中枢神经系统淋巴瘤的长期随访：多中心原发性肝癌和放射学的结果OSKO-53 II期研究
3. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hämatologie und Onkologie OSHO-53 phase II study [J] . T. Kiefer1* C. Hirt1 C. Späth1 F. Schüler23 H. K. Al-Ali2 H.-H. Wolf4 R. Herbst5 G. Maschmeyer6 K. Helke7 C. Kessler8 D. Niederwieser2 C. Busemann1 H. Schroeder9 S. Vogelgesang10 M. Kirsch11 M. Montemurro12 W. H. Krüger1 and G. Dölken1 for the Ostdeutsche Studiengruppe Hämatologie und Onkologie Annals of Oncology . 2012,第7期

机译：大剂量化学疗法加自体干细胞移植和适应性全脑放疗对新诊断的原发性中枢神经系统淋巴瘤的长期随访：多中心Ostdeutsche StudiengruppeHämatologie和Onkologie OSHO-53的II期研究结果
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Phase I and II Study of Induction Chemotherapy With Methotrexate Rituximab and Temozolomide Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227 [O] . Jon Glass, Minhee Won, Christopher J. Schultz, -1

机译：甲氨蝶呤利妥昔单抗和替莫唑胺全脑放疗和替莫唑胺照射后治疗原发性中枢神经系统淋巴瘤的一期和二期研究：NRG肿瘤学RTOG 0227
6. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227 [O] . Jon Glass, Minhee Won, Christopher J. Schultz, 2016

机译：甲氨蝶呤，利妥昔单抗和替莫唑胺诱导化疗的II和II研究，其次是全脑放射治疗和PostImradiation Temozolomide用于原发性CNS淋巴瘤：NRG肿瘤学RTOG 0227

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号